Top

Published in:

Open Access 01-12-2021 | Long-COVID Syndrome | Letter to the editor

Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Authors: Max Borsche, Dirk Reichel, Anja Fellbrich, Anne S. Lixenfeld, Johann Rahmöller, Eva-Juliane Vollstedt, Bandik Föh, Alexander Balck, Christine Klein, Marc Ehlers, Andreas Moser

Published in: Neurological Research and Practice | Issue 1/2021

Abstract

Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.

Available only for authorised users

Alexopoulos, H., Magira, E., Bitzogli, K., Kafasi, N., Vlachoyiannopoulos, P., Tzioufas, A., … Dalakas, M. C. (2020). Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. Neurology – Neuroimmunology & Neuroinflammation, 7(6), e893. https://doi.org/10.1212/NXI.0000000000000893.CrossRef

Brison, E., Jacomy, H., Desforges, M., & Talbot, P. J. (2011). Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein. Journal of Virology, 85(23), 12464–12473. https://doi.org/10.1128/JVI.05576-11.CrossRefPubMedPubMedCentral

Förster, M., Weyers, V., Küry, P., Barnett, M., Hartung, H.-P., & Kremer, D. (2020). Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy ‘gone viral’. Brain Communications, 2(2), fcaa149. https://doi.org/10.1093/braincomms/fcaa149

Josephson, S. A., & Kamel, H. (2020). Neurology and COVID-19. JAMA, 324(12), 1139–1140. https://doi.org/10.1001/jama.2020.14254.CrossRefPubMed

Matschke, J., Lütgehetmann, M., Hagel, C., Sperhake, J. P., Schröder, A. S., Edler, C., … Glatzel, M. (2020). Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurology, 19(11), 919–929. https://doi.org/10.1016/S1474-4422(20)30308-2.CrossRefPubMed

Oeltzschner, G., Wijtenburg, S. A., Mikkelsen, M., Edden, R. A. E., Barker, P. B., Joo, J. H., … Smith, G. S. (2019). Neurometabolites and associations with cognitive deficits in mild cognitive impairment: A magnetic resonance spectroscopy study at 7 Tesla. Neurobiology of Aging, 73, 211–218. https://doi.org/10.1016/j.neurobiolaging.2018.09.027.CrossRefPubMed

Rass, V., Beer, R., Schiefecker, A. J., Kofler, M., Lindner, A., Mahlknecht, P., et al. (2021). Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. European Journal of Neurology, online ahead of print. https://doi.org/10.1111/ene.14803

Sasannejad, C., Ely, E. W., & Lahiri, S. (2019). Long-term cognitive impairment after acute respiratory distress syndrome: A review of clinical impact and pathophysiological mechanisms. Critical Care, 23(1), 352. https://doi.org/10.1186/s13054-019-2626-z.CrossRefPubMedPubMedCentral

Taquet, M., Geddes, J. R., Husain, M., Luciano, S., & Harrison, P. J. (2021). 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records. Lancet Psychiatry, 8(5), 416–427. https://doi.org/10.1016/S2215-0366(21)00084-5.CrossRefPubMedPubMedCentral

Title: Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19
Authors: Max Borsche
Dirk Reichel
Anja Fellbrich
Anne S. Lixenfeld
Johann Rahmöller
Eva-Juliane Vollstedt
Bandik Föh
Alexander Balck
Christine Klein
Marc Ehlers
Andreas Moser
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Long-COVID Syndrome
SARS-CoV-2
COVID-19
Published in: Neurological Research and Practice / Issue 1/2021
Electronic ISSN: 2524-3489
DOI: https://doi.org/10.1186/s42466-021-00135-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions

Variability of computed tomography angiography coverage of lung parenchyma in acute stroke

Diagnosis and treatment of neurogenic dysphagia – S1 guideline of the German Society of Neurology

Mechanical thrombectomy in patients with cervical artery dissection and stroke in the anterior or posterior circulation – a multicenter analysis from the German Stroke Registry

Chromium and cobalt intoxication mimicking mitochondriopathy

Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid – no clear evidence of positive disease modifying effects